GlobeNewswire: Novo Nordisk A/S Contains the last 10 of 3731 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T16:01:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2851536/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=50848Novo Nordisk A/S - share repurchase programme2024-03-25T11:58:23Z<![CDATA[Bagsværd, Denmark, 25 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/03/25/2851429/0/en/Novo-Nordisk-to-acquire-Cardior-Pharmaceuticals-and-strengthen-pipeline-in-cardiovascular-disease.html?f=22&fvtc=4&fvtv=50848Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease2024-03-25T09:59:55Z<![CDATA[Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.]]>https://www.globenewswire.com/news-release/2024/03/25/2851368/0/en/Novo-Nordisk-A-S-Articles-of-Association-2024.html?f=22&fvtc=4&fvtv=50848Novo Nordisk A/S - Articles of Association 20242024-03-25T07:51:32Z<![CDATA[Novo Nordisk's Articles of Association 2024]]>https://www.globenewswire.com/news-release/2024/03/25/2851368/0/da/Vedt%C3%A6gter-for-Novo-Nordisk-A-S-2024.html?f=22&fvtc=4&fvtv=50848Vedtægter for Novo Nordisk A/S 20242024-03-25T07:51:32Z<![CDATA[Vedtægter for Novo Nordisk A/S 2024]]>https://www.globenewswire.com/news-release/2024/03/21/2850423/0/en/Awiqli-once-weekly-basal-insulin-icodec-recommended-for-approval-for-the-treatment-of-diabetes-by-the-European-regulatory-authorities.html?f=22&fvtc=4&fvtv=50848Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities2024-03-21T15:55:51Z<![CDATA[Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli® (the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults.]]>https://www.globenewswire.com/news-release/2024/03/21/2850373/0/en/Resolutions-from-the-Annual-General-Meeting-of-Novo-Nordisk-A-S.html?f=22&fvtc=4&fvtv=50848Resolutions from the Annual General Meeting of Novo Nordisk A/S2024-03-21T14:59:20Z<![CDATA[Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting.]]>https://www.globenewswire.com/news-release/2024/03/18/2847931/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=50848Novo Nordisk A/S - share repurchase programme2024-03-18T14:18:20Z<![CDATA[Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/03/11/2843796/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=50848Novo Nordisk A/S - share repurchase programme2024-03-11T12:46:36Z<![CDATA[Bagsværd, Denmark, 11 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/03/08/2843283/0/en/Wegovy-approved-in-the-US-for-cardiovascular-risk-reduction-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease.html?f=22&fvtc=4&fvtv=50848Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease2024-03-08T18:42:10Z<![CDATA[Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).]]>https://www.globenewswire.com/news-release/2024/03/07/2841943/0/en/Highlights-to-be-presented-at-Novo-Nordisk-s-Capital-Markets-Day-2024.html?f=22&fvtc=4&fvtv=50848Highlights to be presented at Novo Nordisk’s Capital Markets Day 20242024-03-07T07:00:42Z<![CDATA[Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.]]>